|

How Long Until Psychedelic Stocks Payoff?πŸ„πŸš€| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more

How long until Psychedelic Stocks Payoff?πŸ„πŸš€

To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:

Psychedelic Spotlight

While researching a possible investment into psychedelic stocks, you have almost certainly heard the refrain of, β€œIt’s a long-term investment.” I myself, in my many videos for The Psychedelic Investor and articles for PsychedelicSpotlight.com, have probably said this over 100 times.

And while the thesis for investing in psychedelic stocks is appealing, having a timeline clearer than β€œit’s a long term investment” is necessary before deciding whether it is worth the risk.

In this video, therefore, I endeavor to answer a big question: β€œWhen will psychedelic stocks provide a significant return on investment?”

Or, translated to Reddit-speak: when moon?

To start, I feel it’s necessary to give the warning that the answer may be never. To be clear, while I personally believe in the potential for psychedelic stocks such as MindMed (Nasdaq: MNMD, NEO: MMED) and Cybin (NYSE: CYBN, NEO: CYBN), the entire psychedelic medicines industry is inherently speculative and there is no guarantee of success. Yes, the science right now suggests that treatments such as MDMA therapy for PTSD and Ketamine therapy for addiction will disrupt the mental healthcare market, but this needs to be confirmed in larger studies.

There will be two separate turning points for psychedelic medicines and the companies that produce them: the legalization of the first psychedelic medicines, and the legalization of improved next-generation psychedelics.

The first will happen relatively soon.

#PsychedelicStocks #MindMed #Cybin

Similar Posts

  • Interview With Chris Kilham, Medicine Hunter Inc.

    Chris works alongside companies to develop plant-based food and medicinal products, helping turn them into market successes. He has conducted medicinal plant research and sustainable botanical sourcing in over 45 countries, and has been featured on a number of platforms such as The New York Times, The Dr. Oz Show, Business Insider, CNN, VICE, and much more.Β 

  • Interview With Tesla La Touche

    In this episode of the Psychedelic Spotlight podcast, we spend some time with Tesla La Touche who is the Founder and CEO of Aphrodite Health, the first ever female-founded biotech company within the medicinal psychedelic industry.Β 

  • Will MAPS IPO? The FIRST American Psychedelic ETF (PSY), New LSD Studies & More

    There were LOTS of general news important for the psychedelic industry as a whole and very important study results that will influence some of our favorite stocks such as MindMed (MMED / MNMD / MMQ) and Compass Pathways (CMPS)!

    In today’s episode we’ll cover a new American psychedelic ETF which is hitting the market under ticker symbol PSY, some new psilocybin and LSD studies, whether MAPS will turn into a public company and some updates on the California and New York bills we have been covering for a while now.

    Enjoy the episode!

    Timestamps:
    0:00 – Intro
    0:40 – The First American Psychedelic ETF (PSY)
    5:50 – MAPS Considering An IPO?
    12:28 – Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical SSRIs
    15:29 – New Study On How LSD Affects The Brain
    21:08 – The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD
    23:00 – New York Bill Proposes State-Sponsored Psychedelic Research Institute

    Links:
    New Psychedelic ETF (NYSE : PSY) :
    https://www.defianceetfs.com/psy/
    https://psychedelicspotlight.com/psy-first-u-s-psychedelic-etf/

    Maps Considering An IPO?:
    https://www.reddit.com/r/shroomstocks/comments/nqoy0z/maps_considering_ipo/
    https://youtu.be/v2HycPpjf6Y

    Study Shows Psilocybin Assisted-Therapy Is 4-Times More Effective Than Typical Antidepressants:
    https://thedalesreport.com/psychedelics/study-shows-psilocybin-assisted-therapy-4-times-more-effective-than-typical-antidepressants/

    New Study On How LSD Affects The Brain:
    https://www.theguardian.com/science/2021/may/19/acid-test-scientists-show-how-lsd-opens-doors-of-perception

    The California Senate Has Approved a Bill To Legalize the Possession Of Psychedelics Like Psilocybin And LSD:
    https://www.marijuanamoment.net/california-senate-approves-bill-to-legalize-possession-of-psychedelics-like-psilocybin-and-lsd/

    New York Bill Proposes State-Sponsored Psychedelic Research Institute:
    https://psychedelicspotlight.com/new-york-bill-psychedelic-research-institute/

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! πŸ™Œ

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MAPS

  • Interview With Timothy Ko

    CEO of Entheon Biomedical, Timothy Ko, discusses how the company plans to utilize the psychedelic compound, DMT, to treat a variety of addictions.